3M Drug Delivery Systems Spring Show Guide - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

3M Drug Delivery Systems Spring Show Guide

For pharmaceutical and biotech companies seeking innovation, quality and performance, 3M is the global expert in manufacturing from start-to-finish. See us at Interphex New York (April 23-25), booth # 2143, to find how trusted inhalation and transdermal drug delivery technologies from 3M can meet your product needs!

3M Drug Delivery Systems, St. Paul, MN |  www.3M.com/DDS  | tel. 800-643-8086

Shows attending:

  • PDA (Nov 5-6 in Switzerland) — (Booth 76)
  • BIO (attending, but no booth)
  • Interphex (Apr 23-25 NY) — Booth 2143
  • AAPS Biotech (Nov 10-14 TX) — Booth 4023
  • RDD (May 21-24 Berlin) — Booth TBD
  • MD&ME June 18-20 — Booth 3511
  • CRS (July 21-24 Hawaii — Booth 113
  • PODD (Oct 10-11 Boston) — Booth TBD
  • World Vaccine Congress (Oct 16-17) — Booth TBD
  • DDS (Dec 11-13 Edinburgh, UK) — Booth TBD


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here